ERBB2 and breast carcinoma: For example, MAPK inhibition in different types of cancer cells addicted to mutant KRAS or RTKs, such as EGFR (NSCLC), HER2 (breast cancer) or ALK (neuroblastoma), can provoke an increase in the secretion of fibroblast growth factor and interleukin-6.